Masimo Earnings Reports

Masimo reported a net loss of $349.6 million for Q4 2024 due to impairment charges related to Sound United. Revenue for the quarter increased by 9% year-over-year, driven by strong healthcare segment performance. Non-GAAP net income per diluted share grew by 44% compared to the prior year period.

Masimo Corporation announced financial results for the third quarter ended September 28, 2024. Consolidated revenue was $504.6 million, with healthcare revenue at $343.3 million and non-healthcare revenue at $161.3 million. GAAP net income per diluted share was $0.18, while non-GAAP net income per diluted share was $0.98.

Masimo reported consolidated revenue of $496.3 million for Q2 2024, with healthcare revenue at $343.9 million and non-healthcare revenue at $152.4 million. GAAP net income per diluted share was $0.29, and non-GAAP net income per diluted share was $0.86. The company increased its full-year 2024 guidance for healthcare revenue, consolidated operating income, and consolidated EPS.

Masimo's consolidated revenue was $492.8 million, with healthcare revenue at $339.6 million and non-healthcare revenue at $153.2 million. The company reported a GAAP net income per diluted share of $0.35 and a non-GAAP net income per diluted share of $0.77.

Masimo reported consolidated revenue of $548.9 million for Q4 2023. GAAP net income per diluted share was $0.63, and non-GAAP net income per diluted share was $1.25. The company's healthcare sector revenue reached $339.9 million, while the non-healthcare sector contributed $209.0 million.

Masimo's consolidated revenue for Q3 2023 was $478.9 million, with healthcare revenue at $307.8 million and non-healthcare revenue at $171.1 million. The company's GAAP net income per diluted share was $0.20, while the non-GAAP net income per diluted share was $0.63. The performance was within the company's guidance range, with the healthcare business undergoing a transition away from COVID-era conditions.

Masimo Corporation reported consolidated revenue of $455.3 million for Q2 2023, with healthcare revenue at $281.1 million and non-healthcare revenue at $174.2 million. GAAP net income was $15.7 million, or $0.29 per diluted share, while non-GAAP net income was $33.7 million, or $0.62 per diluted share. The company gained new hospital customers at a record level but is disappointed with the results due to lower inpatient volumes and delayed large orders.

Masimo reported consolidated revenue of $565.0 million, representing an 85.7% increase compared to the first quarter of 2022. Healthcare revenue grew by 14.0%, while non-healthcare revenue was $218.3 million. GAAP earnings per diluted share were $0.39, and non-GAAP earnings per diluted share were $0.87.

Masimo reported consolidated revenue of $617.0 million, representing an 88.3% increase. Healthcare revenue reached $351.9 million, with a 7.4% reported growth and 10.1% constant currency growth. The company's GAAP net income was $41.1 million, or $0.76 per diluted share, and non-GAAP net income was $71.3 million, or $1.32 per diluted share.

Masimo reported strong Q3 2022 results, with consolidated revenue of $549.3 million, a 78.7% increase compared to Q3 2021. Healthcare revenue grew by 6.4% to $327.2 million, and non-healthcare revenue was $222.1 million. GAAP net income was $37.9 million, or $0.70 per diluted share, while non-GAAP net income was $53.9 million, or $1.00 per diluted share.

Masimo reported consolidated revenue of $565.3 million, representing 85.3% growth compared to Q2 2021. Healthcare revenue was $357.0 million, a 17.0% increase, and non-healthcare revenue was $208.3 million. GAAP net income was $18.1 million, or $0.33 per diluted share, while non-GAAP net income was $74.8 million, or $1.35 per diluted share.

Masimo reported product revenue of $307.4 million, GAAP net income per diluted share of $1.00, and non-GAAP net income per diluted share of $0.94 for the third quarter of 2021.

Masimo reported strong second quarter results with product revenue increasing to $305.1 million and non-GAAP net income per diluted share of $0.94, exceeding expectations due to a strong increase in single-patient-use sensors.

Masimo announced its Q1 2021 financial results, revealing a product revenue increase of 10.9% to $299.0 million compared to Q1 2020. GAAP net income was $53.4 million, or $0.92 per diluted share.

Masimo reported a 19.2% increase in total revenue for the fourth quarter of 2020, reaching $295.1 million compared to $247.5 million in the fourth quarter of 2019. GAAP net income per diluted share was $1.21, and non-GAAP net income per diluted share was $0.98.

Masimo announced its Q3 2020 financial results, with total revenue increasing by 21.4% to $278.1 million compared to Q3 2019. Product revenue also increased by 21.5% to $278.1 million. GAAP net income was $49.4 million, or $0.85 per diluted share, while non-GAAP net income was $46.8 million, or $0.80 per diluted share.

Masimo reported a 31.0% increase in total revenue to $301.0 million for Q2 2020, with product revenue also up by 31.1%. GAAP net income per diluted share was $0.96, and non-GAAP net income per diluted share was $0.85. Shipments of noninvasive technology boards and instruments reached a record 165,600.

Masimo reported a 16.4% increase in total revenue to $269.6 million for Q1 2020, driven by a 16.9% increase in product revenue. GAAP net income per diluted share was $1.12, and non-GAAP net income per diluted share was $0.97. The company shipped 72,100 noninvasive technology boards and monitors, a 13.2% increase year-over-year.

Masimo reported a total revenue of $247.5 million for Q4 2019, with product revenue increasing by 11.8% to $247.4 million. The company's GAAP net income per diluted share was $0.92, and non-GAAP net income per diluted share was $0.91.